Affibody Ab

Vladimir Tolmachev

Joachim Feldwisch

Fredrik Frejd

Christofer Lendel

Lars Abrahmsén

Nina Herne

HER2 binding polypeptides comprising the amino acid sequence EXRNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLXE AKKLNDSQ wherein Xin position 2 is M, I or L, and Xin position 39 is S or C (SEQ ID NO:1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.

Polypeptides having affinity for HER2

HER2 binding polypeptides comprising the amino acid sequence EXRNAYWEIA LLPNLTNQQK RAFIRKLYDD PSQSSELLXE AKKLNDSQ wherein Xin position 2 is M, I or L, and Xin position 39 is S or C (SEQ ID NO: 1) are disclosed. Moreover, such peptides comprising a chelating environment are disclosed. Also radiolabeled polypeptides formed by the peptides comprising a chelating environment and radionuclides are disclosed. Furthermore, methods of in vivo imaging of the body of a mammalian subject having or suspected of having a cancer characterized by overexpression of HER2 comprising administration of such a radiolabeled polypeptide followed by obtainment of an image of the body using a medical imaging instrument and also methods of treating such cancer are disclosed. Furthermore, the use of such a radiolabeled polypeptide in diagnosis and treatment of cancer characterized by overexpression of HER2. Nucleic acids encoding the polypeptides, expression vectors comprising the nucleic acids and host cells comprising the expression vectors are also disclosed.

Growing community of inventors

Uppsala, Sweden

Vladimir Tolmachev